FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 20:48:34 14/06/2024 BST | ||
| 0.17 EUR | -1.73% |
|
| Current month | -19.05% | ||
| 1 month | -39.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.17 | -1.73% |
| 13/06/24 | 0.173 | -3.35% |
| 12/06/24 | 0.179 | +5.92% |
| 11/06/24 | 0.169 | +2.42% |
| 10/06/24 | 0.165 | +0.61% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 08:48 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD33DU |
| ISIN | DE000MD33DU7 |
| Date issued | 31/03/2022 |
| Strike | 598.8 $ |
| Maturity | Unlimited |
| Parity | 646.28 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.48 € |
|---|---|
| Lowest since issue | 0.16 € |
| Spread | 0.001 € |
| Spread % | 0.58% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
